Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase EARLY_PHASE1 1Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 257Breast Neoplasms 173Neoplasms 170Colorectal Neoplasms 156Neoplasm Metastasis 127Melanoma 120Prostatic Neoplasms 118Recurrence 117Leukemia, Myeloid, Acute 117Pancreatic Neoplasms 115Ovarian Neoplasms 112Multiple Myeloma 104Lung Neoplasms 96Stomach Neoplasms 91Squamous Cell Carcinoma of Head and Neck 86Triple Negative Breast Neoplasms 85Glioblastoma 82Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 65Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 63Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 55Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

talimogene laherparepvec 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Ductal × 1 year × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡